Aegerion Deferred Prosecution Agreement

In accordance with the Deferred Prosecution Agreement, Aegerion will implement expanded compliance provisions, including regular certifications to the government on the implementation of these provisions. Young`s concern about the DOJ-Aegerion agreement was that it was a fine entirely imposed on the government, rather that it would have gone to 91 patients who might have been harmed by Aegerion`s behaviour. In a statement to the prosecutor`s office, Young said, “I think you should pay more attention to the real people who were injured here.” He added: “I feel so strong that people who have been harmed by this crime should receive some compensation,” as the Boston Globe quotes. Apart from the practices admitted as part of the admission of guilt and agreement with the adjourned proceedings, the claims that were settled in the civil transaction are merely allegations and no evidence of liability has been made. September 22, 2017, Aegerion Pharmaceuticals has launched a thorough Investigation by the Department of Justice (DOJ) into the company`s U.S. business activities regarding Juxtapid, an anti-lipid drug used to treat homozygotic familial hypercholesterolemia (HoFH).1 As described below, DOJ has relied on a number of statutes and a complex web of agreements to address a wide range of allegedly objectionable behavior. , including: in a deferred prosecution agreement for the settlement of a charge, Aegerion admitted that Aegerion conspired to injure HIPAA, 42 U.C No. 1320d-6 (a) and 1320-6 (b) (3), and acknowledged that he had conspired to obtain personal patient health information without the patient`s authorization for commercial benefit. In accordance with the Deferred Prosecution Agreement, Aegerion will implement expanded compliance provisions, including regular certifications to the government on the implementation of these provisions. Plea agreement. Aegerion pleaded not only guilty, but also paid a $6.2 million fine and $1 million in compensation.

The means of the plea and application also require that Aegerion, its chairman and the board of directors of the parent company be required to verify and certify compliance with the means and the approval order each year for three years. “Today`s agreement shows that we will not allow pharmaceutical manufacturers to provide the medical community with false and incomplete information about their products, thereby endangering the health and safety of our citizens,” said the OIG Special Representative (

  • Facebook
  • Twitter
  • Google Bookmarks
  • Google Buzz
  • LinkedIn
  • Tumblr
  • Yahoo! Bookmarks
  • E-Mail

Comments are closed.